Twist Bioscience Corporation (TWST)
TWSTNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$135.80
+15.01 (+12.43%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $8.97bn
- P/E
- –
- EPS, last 4 quarters
- $-2.13
- Dividend yield
- –
- Day range
- –
- 52-week range
- $23.30 to $219.71
- Average volume
- 2.47m
- Previous close
- $120.79
Analysts
7 coveringBuy5 buy, 1 hold, 1 sell
Targets a year out average $168.88, +24.4% from here
Earnings
next estimate $-0.4400Next report Nov 12, 2026
Sep 2025
-12.5%
Dec 2025
-4.2%
Mar 2026
-14.8%
Jun 2026
-12.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $99.01m | $103.70m | $110.72m | $118.38m |
| Gross profit | $50.84m | $53.97m | $57.12m | $62.45m |
| Operating income | -$29.93m | -$32.90m | -$45.86m | -$36.28m |
| Net income | -$27.14m | -$30.51m | -$44.02m | -$35.05m |
Last four quarters: revenue $431.80m, margin -31.7%, free cash flow -$93.12m
News
8 latest- ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue EstimatesZacks · 13 hours ago
- Noteworthy ETF Inflows: IWM, BTSG, FROG, TWSTBNK Invest · 3 days ago
- Meet the Unstoppable Vanguard ETF Beating the S&P 500 and the Dow Jones in 2026The Motley Fool · 4 days ago
- ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue EstimatesZacks · 5 days ago
- Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue EstimatesZacks · 7 days ago
- ARK Innovation ETF Experiences Big OutflowBNK Invest · Oct 28, 2026
- Twist Bioscience Consensus Price Target Increased by 29.51% to $153.59Fintel · Oct 23, 2026
- FYC, TXG, TWST, RNG: Large Inflows Detected at ETFBNK Invest · Oct 12, 2026
The company
At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal - more experiments, more iterations, more chances for remarkable discoveries. Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- twistbioscience.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.